DK1292586T3 - Fremgangsmåde til fremstilling af pyrazolopyrimidinoner - Google Patents

Fremgangsmåde til fremstilling af pyrazolopyrimidinoner

Info

Publication number
DK1292586T3
DK1292586T3 DK01936737T DK01936737T DK1292586T3 DK 1292586 T3 DK1292586 T3 DK 1292586T3 DK 01936737 T DK01936737 T DK 01936737T DK 01936737 T DK01936737 T DK 01936737T DK 1292586 T3 DK1292586 T3 DK 1292586T3
Authority
DK
Denmark
Prior art keywords
pyrazolopyrimidinones
preparation
Prior art date
Application number
DK01936737T
Other languages
Danish (da)
English (en)
Inventor
Peter James Dunn
Catherine Dunne
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26244540&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1292586(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0015472A external-priority patent/GB0015472D0/en
Priority claimed from GB0105857A external-priority patent/GB0105857D0/en
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK1292586T3 publication Critical patent/DK1292586T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Communicable Diseases (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK01936737T 2000-06-22 2001-06-11 Fremgangsmåde til fremstilling af pyrazolopyrimidinoner DK1292586T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0015472A GB0015472D0 (en) 2000-06-22 2000-06-22 Novel process for the preparation of pyrazolopyrimidinones
GB0105857A GB0105857D0 (en) 2001-03-09 2001-03-09 Novel process for the preparation of pyrazolopyrimidinones

Publications (1)

Publication Number Publication Date
DK1292586T3 true DK1292586T3 (da) 2004-08-30

Family

ID=26244540

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01936737T DK1292586T3 (da) 2000-06-22 2001-06-11 Fremgangsmåde til fremstilling af pyrazolopyrimidinoner

Country Status (29)

Country Link
EP (1) EP1292586B1 (es)
JP (1) JP2004501142A (es)
KR (1) KR100525698B1 (es)
CN (1) CN100338047C (es)
AP (1) AP2001002194A0 (es)
AR (1) AR028740A1 (es)
AT (1) ATE272626T1 (es)
AU (2) AU6259701A (es)
BR (1) BR0111581A (es)
CA (1) CA2411961C (es)
CZ (1) CZ20024176A3 (es)
DE (1) DE60104691T2 (es)
DK (1) DK1292586T3 (es)
DO (1) DOP2001000190A (es)
ES (1) ES2223863T3 (es)
HK (1) HK1054926A1 (es)
HU (1) HUP0301183A3 (es)
IL (1) IL153532A0 (es)
MX (1) MXPA02012884A (es)
MY (1) MY124903A (es)
PA (1) PA8519801A1 (es)
PE (1) PE20020105A1 (es)
PL (1) PL359651A1 (es)
PT (1) PT1292586E (es)
SV (1) SV2002000503A (es)
TN (1) TNSN01093A1 (es)
TR (1) TR200401983T4 (es)
WO (1) WO2001098284A1 (es)
YU (1) YU93902A (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2310144B1 (es) * 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
PL2228370T3 (pl) * 2007-12-28 2012-10-31 Topharman Shanghai Co Ltd N-{1-[3-(2-etoksy-5-(4-etylopiperazynylo)benzenosulfonylo)-4,5-dihydro-5-okso-1,2,4-triazyn-6-yl]etylo}butyroamid, sposób jego wytwarzania i zastosowanie
CN101747282A (zh) * 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
CA2770471A1 (en) 2009-08-07 2011-02-10 Ranbaxy Laboratories Limited Processes for the preparation of vardenafil
JP2013517281A (ja) * 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッド 化合物及び方法
MX2010006227A (es) 2010-06-07 2011-12-14 World Trade Imp Exp Wtie Ag Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.
FR2970967B1 (fr) 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2689778A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
BR112019006490B1 (pt) * 2016-10-24 2023-11-28 Fmc Corporation Composto, composições fungicidas e métodos para o controle das doenças dos vegetais

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9822238D0 (en) * 1998-10-12 1998-12-09 Pfizer Ltd Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof
EP1002798A1 (en) * 1998-11-20 2000-05-24 Orchid Chemicals & Pharmaceuticals Ltd. An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative

Also Published As

Publication number Publication date
DOP2001000190A (es) 2002-05-15
TNSN01093A1 (fr) 2005-11-10
AP2001002194A0 (en) 2002-12-21
CN1437589A (zh) 2003-08-20
BR0111581A (pt) 2003-03-25
PE20020105A1 (es) 2002-02-21
EP1292586B1 (en) 2004-08-04
AU2001262597B2 (en) 2005-10-20
MY124903A (en) 2006-07-31
CA2411961A1 (en) 2001-12-27
HUP0301183A2 (hu) 2003-08-28
DE60104691T2 (de) 2005-01-13
HK1054926A1 (en) 2003-12-19
CA2411961C (en) 2007-02-06
WO2001098284A1 (en) 2001-12-27
PA8519801A1 (es) 2002-04-25
PL359651A1 (en) 2004-08-23
IL153532A0 (en) 2003-07-06
EP1292586A1 (en) 2003-03-19
CZ20024176A3 (cs) 2004-01-14
ES2223863T3 (es) 2005-03-01
JP2004501142A (ja) 2004-01-15
PT1292586E (pt) 2004-11-30
AU6259701A (en) 2002-01-02
KR20030031912A (ko) 2003-04-23
TR200401983T4 (tr) 2004-09-21
DE60104691D1 (de) 2004-09-09
HUP0301183A3 (en) 2006-02-28
MXPA02012884A (es) 2003-05-14
CN100338047C (zh) 2007-09-19
YU93902A (sh) 2005-11-28
SV2002000503A (es) 2002-07-03
KR100525698B1 (ko) 2005-11-03
AR028740A1 (es) 2003-05-21
ATE272626T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1296656T3 (da) Fremgangsmåde til fremstilling af et præparat
CY2007029I2 (el) Μεθοδος για την παρασκευη υποκατεστημενων οκτανοϋλ-αμιδιων
DK1277722T3 (da) Fremgangsmåde til fremstilling af methanol
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
DK1326585T4 (da) Fremgangsmåde til fremstilling af pulverformuleringer
DK1259512T3 (da) Pteridinforbindelser til behandling af psoreasis
DK1309581T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1380121T3 (da) Fremgangsmåde til fremstilling af oxazolidinoner
DK1345939T3 (da) Fremgangsmåde til fremstilling af sulfonamidsubstituerede imidazotriazinoner
DK1263717T3 (da) Fremgangsmåde til fremstilling af methionin
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
DK1326836T3 (da) Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin
DK1456229T3 (da) Fremgangsmåe til fremstilling af echinocandin-derivater
DK1292586T3 (da) Fremgangsmåde til fremstilling af pyrazolopyrimidinoner
DK1296970T3 (da) Fremgangsmåde til fremstilling af citalopram
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
DK1203000T3 (da) Fremgangsmåde til fremstilling af phosphonomethylglycin
DK1299181T3 (da) Fremgangsmåde til fremstilling af formaldehyd
DK1294694T3 (da) Fremgangsmåde til fremstilling af quinolinderivater
NO20030515L (no) Fremgangsmåte for fremstilling av dinapsolin
DK1309607T3 (da) Fremgangsmåde til fremstilling af LHRH-antagonister
DK1272486T3 (da) Fremgangsmåde til fremstilling af 7-(pyrazol-3-yl)benzoxazoler
DK1165483T3 (da) Fremgangsmåde til fremstilling af carbonylfluorid
DK1254159T3 (da) Fremgangsmåde til fremstilling af acetylamidiniophenylalanylcyclohexylglycylpyridylalaninamider